Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$21.22 USD
+3.29 (18.35%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.17 -0.05 (-0.24%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 81 - 100 ( 192 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Pivotal ENHANCE-2 Study Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-2 Enrollment Complete, Topline Anticipated in Q3:22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
48wk ENHANCE-1 Subset Enrollment Complete, Eyes on Topline ENHANCE Data in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-1 48-Week Subset Enrollment Completion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Program to Yield Data This Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
TQT Study Complete, Looking Ahead to Topline Ph3 ENHANCE Results in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q3: Ph 3 Enrollment Completion by YE:21, Topline Data Readouts in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Providing a Breath of Air to Diseased Lungs; Initiate at Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q2: Executing and ENHANCE-ing; On-Track to Complete Ph3 Enrollment by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Key Takeaways from Virtual NDR on May 25 and 26
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
KOL Highlights Ensifentrine?s Differentiated Profile; Inflection Points in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L